THIODEAZAPURINE DERIVATIVES

Abstract: 7-Deazapurine derivatives of the formula: wherein R₁ is hydrogen atom or an acyl group and R₄ and R₅ each is a hydrogen atom or a hydrocarbon residue which may optionally have one or more substituents or R₄ and R₅, togeth­ er with the adjacent nitrogen atom, form a cyclic amino group are useful as an anti-tumor agent, microbicide or disinfectant.

Description: THIODEAZAPURINE DERIVATIVES This invention relates to novel 7-deazapurine derivatives and a process for production thereof. Natural 6-oxo-modified bases (for example, Q base, Pre Q1 base) having the same nucleus as that of compounds of this invention are widely distributed in life as constituents of certain tRNA (tRNA Y , tRNA , tRNAASP and tRNAASn). These bases are situated at the first position of the anticodons of the aforementioned-tRNAs and play an important biological role by recognizing the genetic information from mRNA directly and being involved in protein synthesis. With the recent advance of fundamental biochemical research, in particular, the structures of tRNAs and the role they play in vital phenomena have been elucidated one after another and the differences in tRNA between a cancer cell and a normal cell have also been clarified. One of the differences is that in a cancer cell the uptake of Q bases into tRNA precursors is incomplete and there invariably exist Q-deficient tRNAs. It has also been observed that when a Q base is supplied from an external source, such a Q-deficient tRNA takes the Q base into the predetermined position (the first letter of the anticodon) and thereby returns to the normal tRNA and that generally the uptake of Q bases is not observed in normal cells but is specific to cancer cells [Nishimura S., Taisha (Metabolism) Vol. 17, Special Issue [Gann (Cancer) 80], pp.127-136 (l980). Under the circumstances the present inventors studied various derivatives of such 6-oxo-modified bases and found that the compounds obtainable on transformation of the 6position of such bases to a thio group are novel compounds having excellent antitumor and antibiotic activities. These studies were followed by further studies which led to completion of this invention. This invention relates to Cl) a 7-deazapurine derivative of the formula: EMI2.1 wherein R1 is hydrogen atom or an acyl group, and R4 and R5 each is a hydrogen atom or a hydrocarbon residue which may optionally have one or more substituents or R4 and R5, together with the adjacent nitrogen atom, form a cyclic amino group or a salt thereof, and (2) a method for producing a 7-deazapurine derivative of the formula (I) or a salt thereof, which comprises subjecting a 7-deazapurine derivative of the formula: EMI2.2 wherein R1 is as defined above and R2 and R3 each is an alkyl, alkenyl or aralkyl group containing a methylene group in the position thereof or R2 and R3, together with the adjacent nitrogen atom, form a cyclic amino group, to substitution reaction with an amine of the formula: : EMI2.3 wherein R4 and R5 have the same meaning as defined above. Referring to the above formulae, the acyl group R1 may be those having the molecular weight of not more than about 400. The examples of the acyl group are alkanoyl, arcyl, and so on. The alkancyl group preferably has 1 - 18 carbon atoms, and is exemplified by formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, 2ethylhexanoyl, nonanoyl, decanoyl, undecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, etc. The alkanoyl group having 1 to 10 carbon atoms is preferable among others. The aroyl group preferably contains 7 to 12 carbon atoms and includes, among others, benzoyl, toluoyl, naphthoyl, etc., and the benzoyl group and the like are preferable among others. The groups R2 and R3 may be the same group or different groups. Examples of the alkyl group, which has a methylene group in a-position, include groups containing 1 to 10 carbon atoms such as methyl, ethyl, n-propyl, n-butyl, isobutyl, pentyl! isopentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl, etc. Particularly preferred are alkyl groups of about 1 to 6 carbon atoms. Examples of the alkenyl group represented by RX and R3 include groups containing about 3 to 13 carbon atoms such as allyl(2-propenyl), 2-butenyl, 2-pentenyl, 2-hexenyl, 4propyl-2-pentenyl, cinnamyl, 2-nonyl-2-butenyl, etc. Particularly preferred are alkenyl groups of about 3 to 9 carbon atoms. These alkyl and alkenyl groups may each carry substituent groups in optional substitutable position or positions other than the a-position, and examples of such substituent groups include alkyl groups of about 1 to 4 carbon atoms (e.g.methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl), alkoxy groups of about 1 to 4 carbon atoms (e.g.methoxy, ethoxy, propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy), alkanoyl groups of about 1 to 4 carbon atoms (e.g.formyl, acetyl, propionyl, n-butyryl, iso-butyryl), hydroxy, nitro, halogen (e.g.fluorine, chlorine, bromine, iodine), carboxy, cyano, trifluoromethyl, dialkylamino (e.g. dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino), alkanoylamido (e.g.formamido, acetamido, propionylamido, butyrylamido, isobutyrylamido) and so on. Examples of the aralkyl group represented by R2 or R3 containing a methylene group in the a-position include groups containing about 7 to 12 carbon atoms such as benzyl, phenethyl, 3-phenylpropyl, naphthylmethyl, naphthylethyl, etc. Particularly preferred is benzyl. These aralkyl groups may each carry substituent group or groups in its alkylene moiety other than the a-position and/or its aryl(phenyl) ring, and examples of such substituents include the groups mentioned hereinbefore as examples of the substituent groups of said alkyl and alkenyl groups. Examples of the cyclic amino group which is formed between R2 and R3 taken together with the adjacent nitrogen atom include cyclic amino groups of 5 or 6 members, and each of the cyclic amino groups may contain a second hetero-atom (e.g. N and/or 0) in addition to the adjacent nitrogen atom as a ring member. Specific examples of such cyclic amino groups include l-pyrrolidinyl, l-pyrrolinyl, l-imidazolidinyl, 1-imidazolinyl, l-pyrazolidinyl, 1pyrazolinyl, morpholino, piperidino, l-piperazinyl, etc. These cyclic amino groups may each carry substituent group or groups at any position other than the position (a) adjoining to the nitrogen atom, and examples of such substituent groups include the groups mentioned hereinbefore as examples of the substituent groups of said alkyl and alkenyl groups. Referring to the above formulae, the hydrocarbon residue of R4 and R5 each may for example be those having the molecular weight of not more than about 400, and exemplified by alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl group. The alkyl may for example be an alkyl group of 1 to 18 carbon atoms (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, hexadecyl, octadecyl, 1,2-dimethylpropyl, l-ethylpropyl, 1,2, 2-trimethylpropyl, l-propylbutyl, 2-ethylhexyl). The alkenyl may for example be an alkenyl group of 2 to 12 carbon atoms (e.g. vinyl, allyl, l-methylvinyl, 2-methylvinyl, l-octenyl, l-decenyl). The cycloalkyl may for example be a cycloalkyl group of 3 to 12 carbon atoms (e.g.cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl). The cycloalkenyl may for example be a cycloalkenyl group of 3 to 8 carbon atoms te.g. cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclopentadienyl, cyclohexadienyl, cycloheptadienyl, cyclooctadineyl). The aralkyl may for example be an aralkyl group of 7 to 13 carbon atoms (e.g. benzyl, a-methylbenzyl, phenetyl, diphenylmethyl). The aryl may for example be an aryl group of 6 to 10 carbon atoms (e.g. phenyl, -naphthyl, B- naphthyl). The groups R4 and R5 may taken together with the adjacent nitrogen atom, form a ring. The cyclic group is preferably a 4- to l0-membered ring, such as azetidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, imidazolyl, pyrazolyl, imidazolinyl, piperidino, morpholino, dihydropyridyl, tetrahydropyridyl, N-methylpiperazinyl, N-ethylpiperazinyl, azacycloheptyl, azacyclooctyl, isoindolyl, indolyl, indolinyl, 2-isoindolinyl, azacyclononyl, azacyclodecyl, etc. The hydrocarbon residues R4 and R5 and the cyclic group formed by R4 and R5 as taken together with the adjacent nitrogen atom may be substituted by one to 3 substituents. Examples of such substituents include alkyl groups of 1 to 4 carbon atoms (e.g. methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl), alkoxy groups of 1 to 4 carbon atoms (e.g.methoxy, ethoxy, propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy) which may be substituted by hydroxy, alkanoyl groups of 1 to 4 carbon atoms (e.g. formyl, acetyl, propionyl, nbutyryl, iso-butyryl), alkanoyloxy groups of 1 to 4 carbon atoms (e.g.formyloxy, acetyloxy, propionyloxy, nbutyryloxy, iso-butyryloxy), carboxy, alkoxycarbonyl groups of 2 to 4 carbon atoms (e.g. methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, iso-propoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, t-butoxycarbonyl), halogens (e.g. fluorine, chlorine, bromine, iodine), hydroxy, nitro, cyano, trifluoromethyl, amino, C14 mcplosubstituted amino (e.g. methylamino, ethylamino, propylamino, isopropylamino, butyl amino, carboxymethylamino),C1¯ dialkylamino (e.g. dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, dicarboxymethylamino ), C1¯4 alkancylamino (e.g. formamido, acetamido, propionylamido, butylamido, isobutylamido), etc. It is to be noted that the EMI6.1 group in the formulas (III) and (I) is differe nt fr om the EMI6.2 group in the compounds of formula (it). The molecular weight of amine (III) is preferably not more than about 500. The substitution reaction in accordance with the invention can be effected, for example, by bringing the compound tII) or a salt thereof into contact with the compound (III) or a salt thereof in a (III)/(II) molar ratio of about 1 to 20 in the absence or presence of an adequate solvent at a temperature of about OOC to the boiling point of the solvent employed, preferably at a temperature within the range of about 20 to 1000C, for about one hour to about 5 days. In case the compound (II) is used in the form of a quaternary salt, such as a quaternary salt with methyl bromide, methyl iodide, methyl methanesulfonate, methyl benzenesulfonate or methyl ptoluenesulfonate, the reaction can be effected under milder conditions. The quaternary salt of compound (II) prepared in the above case may be subjected to substitution reaction with the compound (III), either after isolation or directly without isolation. Where R1 is an acyl group, deacylation (elimination of R1) may, as necessary, be effected simultaneously by continuing heating of the reaction mixture at about 70 to 1000C. The deacylation may also be conducted by any known method of hydrolysis (e.g. acid hydrolysis, alkali hydrolysis, ammonolysis). The solvent for the substitution reaction between compound (II) and compound (III) is exemplified as water, methanol, ethanol, propanol, butanoir pentanol, tetrahydrofuran, dioxane, acetonitrile, pyridine, dimethylformamide, dimethyl sulfoxide, sulfolane, and adequate mixtures of these. In cases where the compound (II) or compound (III) is used in the form of a salt, the desired product (I) can advantageously be produced by adjusting the reactant mixture to an optimal pH (generally about 5 to 13) with a base (e.g. sodium hydroxide, potassium hydroxide, lithium hydroxide, barium hydroxide, triethylamine, N-methylmorpholine) or a salt (e.g. sodium chloride, potassium chloride, calcium chloride, sodium carbonate, potassium carbonate, sodium hydrogen carbonate). In cases where the hydrocarbon residues R4 and R5 are substituted, for example, by a carboxy, hydroxy, amino or alkylamino group, a starting compound (III) having such a substituent already protected or protected beforehand (e.g. alkanoyloxy, alkoxycarbonyl, alkanoylamido) by any per se known method [J.F.W. McOmie, Protective Groups in Organic Chemistry, Plenum Press, London and New York (1973)1 may, as necessary, be subjected to substitution reaction with another starting compound (II), followed by elimination of the protective group from the resulting compound (I). The elimination of such protective group is effected by subjecting the protective group-bearing compound to an adequate, generally known protective group elimination reaction. Thus, for instance, an acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, trifluoroacetic acid, boron trifluoride, boron tribromide, hydrogen bromide-acetic acid), or a base te g. lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide, potassium carbonate, sodium carbonate, aqueous ammonia, methylamine, dimethylamine, ethylamine, diethylamine, trimethylamine, triethylamine) is added and the mixture is maintained, in an appropriate solvent (e.g. water, methanol, ethanol, propanol, butanol, dioxane, tetrahydrofuran, methyl ether, ethyl ether, dichloromethane, chloroform, carbon tetrachloride, benzene, toluene, xylene, or an adequate mixture of these), at a temperature of about -150 to 100 C, preferably -100 to 500C, for about 30 minutes to about 100 hours, preferably for about 1 to 20 hours. Alternatively, a catalyst suited for use in catalytic reduction (e.g. palladium, platinum, rhodium, ruthenium, nickel) is added and catalytic reduction is carried out in an appropriate solvent (e.g. water, methanol, ethanol, propanol, butanol, dioxane, tetrahydrofuran, methyl ether, ethyl ether, benzene, toluene, xylene, ethyl acetate, methyl acetate, acetic acid, or an adequate mixture of these) at a temperature of about 10 to 500C for about 1 to 100 hours. The 7-deazapurine derivative (I) produced by the method of the invention can be isolated from the reaction mixture by generally known separation and/or purification methods, such as concentration, solvent extraction, chromatography, and recrystallization. The compound (I), when obtained in the free form, may be converted to a pharmaceutically acceptable salt by the conventional method. As the salt of the compound (I), there are exemplified by mineral acid salts with hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, boric acid, etc., organic acid salts with oxalic acid, tartaric acid, acetic acid, trifluoroacetic acid, methanesulfonic acid, benzensulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, etc., and quaternary salts with methyl bromide, methyl iodide, methyl methanesulfonate, methyl benzenesulfonate, methyl p-toluensulfonate, etc. The compound (I) , when obtained in a salt form other than the quaternary salt form, may, as desired, be converted to the free form. In this instance, the conversion to the free form can easily be effected by subjecting the salt of compound (I) to an adequate, generally known treatment, such as neutralization or anion exchange chromatography. The thus-obtained compounds (I) and salts thereof inhibit the growth of cultured L5178Y cells in vitro and of Meth A, Sarcoma 180 and so forth in vivo and thus have antitumor activity. The compounds (I) or salts thereof, when intraperitoneally administered to mice in a dose of 200 mg/kg, do not cause any death. Therefore, the compounds (I)and salts thereof can be used as antitumor agents for the tumor treatment in warm-blooded animals, especially mammals (e.g.mouse, rat, cat, dog, rabbit, etc.). In using as antitumor agents, they may be administered orally or parenterally either as they are or in the powder, granule, tablet, capsule, suppository or injection form, for instance, which can be prepared in the conventional manner by using pharmacologically acceptable carriers, excipients, diluents and so forth. The dose depends on the animal to be treated, the condition and severity of the disease, the kind of the compound, the route of administration and other factors, and generally amounts to about 10 to 200 mg/kg of body weight per day as compound (I2 for oral administration or about 10 to 100 mg/kg of body weight per day as compound (I) for parenteral administration. Furthermore, the compounds (I) and salts thereof have antiviral and antimicrobial activities against various viruses and microbes. Since they have low toxicity as mentioned above, they can therefore be used as antiviral agents, antimicrobial agents or disinfectants for the prevention and treatment of viral and bacterial infectious diseases in warm-blooded animals, especially in mammals (e.g. mouse, rat, cat, dog, rabbit,human). In using the compounds (I) or salts thereof as microbicides or disinfectants, the compounds (I) or salts thereof may be incorporated into water, an aqueous solution such as isotonic glucose solution or Ringer solution, or a nonaqueous medium such as a vegetable fatty oil (e.g. cotton seed, peanut, corn or sesame oil) in a concentration of about 0.5 to 500 mg/ml. The liquid preparation can be applied to the hand, foot, ear and other parts of mammals for sterilization and disinfection of the application sites. The compounds (I) or salts thereof can also be used orally in the form of tablets containing about 0.5 to 500 mg thereof together with excipients such as lactose, starch or talc in the prevention and treatment of viral and bacterial infectious diseases in mammals. In that case, the dose is 10 to 200 mg/kg of body weight per day on the compound (I) basis. The compound (II), which is a starting material in practicing the method of the invention, can be produced, for example, according to the reaction processes shown below. EMI11.1 In Step A, the compound (IV) can be converted to the reaction product (V) by reacting with a chlorinating agent (e.g. thionyl chloride, phosphorus oxychloride, phosphorus pentachloride, oxalyl chloride, phthaloyl chloride) in a compound (IV)/chlorinating agent molar ratio of about 1 to 1/100 in the absence or presence of an appropriate solvent at about 500C to 1500C for about 30 minutes to about 10 hours. As the solvent usable in the above reaction, there may be mentioned benzene, toluene, xylene, methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, 1,1,2-trichloroethane, 1,1,2,2-tetrachloroethane and acetonitrile, among others. When dimethylaniline, diethylaniline, triethylamine, dimethylformamide or the like is added, the above reaction may possibly be carried out under relatively mild conditions. The thionation in Step B can be effected by bringing the compound (V) into contact with a thionating agent (e.g. hydrogen sulfide, sodium sulfide, thiourea) in a compound (V)/thionating agent molar ratio of about 1 to 1/20 in an inert solvent, generally at about 20"C to 1500C, for about 30 minutes to one day. Usable solvents are water, alcohols (e.g. methanol, ethanol, propanol, butanol, secbutanol, tert-butanol, ethylene glycol, methoxyethanol ethoxyethanol), ethers (e.g. dimethyl ether, diethyl ether, tetrahydrofuran, dioxane, monoglyme, diglyme), halogenated hydrocarbons te.g. dichloromethane, chloroform, carbon tetrachloride), acetonitrile, dimethylformamide, and adequate mixtures of these. The compound (II) can be produced by condensation of the compound (VI) with the compound (VII) in the presence of formaldehyde or an equivalent thereto (Step C). The compound (VI) and compound (VII) may be used in a salt form. Such salt may be of the same kind as mentioned hereinabove with respect to the mineral acid salt or organic acid salt of the compound (I). Said equivalent to formaldehyde includes reagents capable of behaving as an formaldehyde equivalent in the Mannich reaction, such as paraformaldehyde, formalin, methylal, ethylal, piperidinomethylphthalimide and hexamethylenetetramine. In Step D, the compound (II) can be produced by reacting the compound (VI) with the compound (VII) in a (VII)/(VI) molar ratio of about 1 to 50 in the absence or presence of an appropriate solvent at a temperature of from about OOC to the boiling point of the solvent used, preferably within the range of about 20 to 1000C, for about 10 minutes to about 48 hours and then treating the reaction mixture with an acid. Usable solvents include water, methanol, ethanol, propanol, butanol, pentanol, tetrahydrofuran, dioxane, acetonitrile, pyridine, dimethylformamide, dimethyl sulfoxide, sulfolane, and adequate mixtures of these. The rate of reaction and the yield can be increased by adjusting the reactant mixture to an optimal pH (generally about 2 to 10) with an acid (e.g. hydrochloric acid, sulfuric acid, phosphoric acid, boric acid, acetic acid, oxalic acid, tartaric acid, trifluoroacetic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid), a base (e.g. sodium hydroxide, potassium hydroxide, lithium hydroxide, barium hydroxide, ammonia, triethylamine) or a salt (e.g. sodium chloride, calcium chloride, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, ammonium chloride) . As the acid to be used in the final acid treatment, there may be mentioned, for instance, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, boric acid, acetic acid, oxalic acid, tartaric acid, trifluoroacetic acid, methanesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid. The compound (II) can be isolated from the reaction mixture in an adequate manner by any or any combination of usual separation and/or purification methods, such as concentration, solvent extraction, recrystallization and chromatography. When the compound (II) obtained in this way is in the free form, it may be converted to a salt form by the conventional method for use as a starting compound in practicing the method of the invention. The salt of compound (II) includes those salt forms as mentioned hereinabove with respect to the compound (11. In practicing the method of the invention, the compound (III) may be used in the form of a salt. The salt of compound (III) includes those salts as mentioned hereinabove with respect to the compound (IV) and compound CVII) The following experimental, reference and working examples are further illustrative of this invention. Experimental Example 1 The uptake of compound of Example 1 into tRNA 3 *) (8000 cpm), 70 mM of I 3Hj-Guanine labeled tRNA (8000 cpm), 70 mM of tris hydrochloride, 60 mM of magnesium chloride, 0.5 unit of rat liver tRN -guanine transglycosylase and 0.02 OD260 of the compound of Example 1 (which appears hereinafter) (100 'Il) were incubated at 370C for 17 hours. The reaction mixture was applied to a Whatman 3 MM filter paper (h7hatman Co., U.S.A.) and washed 3 times with a 5% aqueous solution of trichloroacetic acid and, then, once each with ethanol/ether (1:1) and ether alone. After drying, the uptake of the test compound was determined in a toluenic scintillation fluid. It was found that the compound of Example 1 had been taken up in 81% of tRNA. *) tRNA with the first letter (base) of its anticodon labeled with { 3Hj guanine. Experimental Example 2 The uptake of the compound of Example 2 into tRNA was determined in the same manner as Experimental Example I. The result was 57%. Experimental Example 3 1 x 104 L5178Y mouse tumor cells were suspended in 2 ml of a RPMI-1640 medium containing 10% of bovine fetal serum, 20 uM of 2-mercaptoethanol and 100 Vg/ml kanamycin (Nissui Pharmaceutical Co., Ltd. Japan), and incubated at 370C for 24 hours before addition of the drug. Using the above culture fluid as a diluent, the compound of Example 1 was diluted 1/4-fold in a series of 5 stages, the maximum concentration of the compound in the medium being 200 pg/ml. The dilutions were further incubated for 72 hours, at the end of which time the cells were counted and the IC50 (50% growth inhibitory concentration) was calculated with the count for the non-treated control group being taken as 100%. The IC50 value was 22 pg/ml. Experimental Example 4 5 x 104 Meth A tumor cells were subcutaneously transplanted into a BALB/c mouse weighing 20 g and starting on the 4th day after transplantation, a solution of the compound of Example 1 in 0.1 ml of distilled water was intraperitoneally injected into the mouse once daily in a dose of 100 mg/kg for 14 consecutive days. On the 35th day after tarnsplantation, the tumor node was enucleated and weighed. Comparison of the weight with that of the non-treated control group showed an inhibition of tumor growth. The tumor growth inhibition rate was 71%. Reference Example 1 Production of 2-amino-4-chloropyrrolo [2, 3-d] pyrimidine 2-Aminopyrrolot2,3-d3pyrimidin-4-one (45 g) was suspended in phosphorus oxychloride (150 ml) and the suspension was stirred at 1100C for 3 hours. The excess amount of phosphorus oxychloride was distilled off under reduced pressure and ice water (600 ml) was added to the residue, whereby the residue was thoroughly dissolved. The solution was cooled with stirring and adjusted to pH 9 with concentrated aqueous ammonia. The resulting precipitate was collected by filtration, washed with water and recrystallized from hot methanol (4 Q) to give the above-identified compound (34.6 g). NMR(DMSO-d6, 60MHz): 6 6.23(d, 1H), 6.40(bs, 3H), 7.05 (d, 1H) IR(KBr) : v 3420, 3330, 3170, 2970, 2820, 1680, 1640, 1620, 1570 cm 1 MeOH max 232, 258, 319 nm Reference Example 2 Production of 4-chloro-2-n-octanoylaminopyrrolof2,3-d]- pyrimidine 2-Amino-4-chloropyrrolot2,3-d]pyriidine (16.9 g) as obtained in Reference Example 1 was suspended and dissolved in dry pyridine (200 ml). With ice-cooling, noctanoyl chloride (21.2 g) was added to the solution, and the temperature was returned to room temperature. The reaction was allowed to proceed for an hour. To the reaction mixture was added 9.9% ethanolic ammonia (w/v) and the mixture was allowed to stand at room temperature for 2 hours. The solvent was then distilled off under reduced pressure and water (500 ml) was added to the residue The mixture was stirred at room temperature for an hour and the insoluble matter was collected by filtration, washed with sodium hydrogen carbonate and water, and dried to give a yellow crystalline powder (23.3 g). This product was recrystallized from 1,2-dimethoxyethane to give the above-identified compound (20.9 g). NMROCDC13/DMSO-d6, 60MHz): 6 0.87(t, 3H), 1.30fobs, 10H), 2.50(t, 2H), 6.43(d, 1H), 7,30cud, lH), 10.37(s, lH), 12.10tubs, 1H) -l IR(KBr): v 3430, 3220, 2920, 1645, 1610, 1585, 1375 cm Reference Example 3 Production of 2-n-octanoylaminopyrrolo L 3-dj pyrimidine- 4-thione 4-Chloro-2-n-octanoylaminopyrrolo [2, 3-dj pyrimidine (19.9 g) as obtained in Reference Example 2 and thiourea t38 g) were suspended and dissolved in 2-methoxyethanol t240 ml). The solution was stirred at 1000C for 25 hours. The solvent was then distilled off under reduced pressure and 1.8% aqueous sodium hydrogen carbonate (300 ml) was added to the residue. The mixture was stirred thoroughly at room temperature and the resulting precipitate was collected by filtration and recrystallized from ethanol to give the above-identified compound (15.7 g). NMR(CDC13/DMSO-d6, 60MHz): 6 0.87(t, 3H), 1.33(bs, 10H), 1.47(t, 2H), 6.63(q, 1H), 6.90(q, 1H), 11.27(bs, 2H), 13.20(bs, 1H) -l IR(KBr): v 3220, 1680, 1635, 1600, 1310 cm Reference Example 4 Production of 5-N ,N-dibenzylaminomethyl-2-octanoylamino- pyrrolo [2, 3-d] pyrimidine-4-thione 2-Octanoylaminopyrrolo [2, 3-dj pyrimidine-4-thione (3.5 g) as obtained in Reference Example 3 and dibenzylamine (9.5 g) were dissolved in water/acetic acid (1:4, 120 ml), and 35% formalin (4.2 g) was added to the solution. The reaction was allowed to proceed at 600C for 14 hours. The solvent was then distilled off under reduced pressure and water (30 ml) was added, followed by further distillation. 2N-HC1 (64 ml) and methanol (100 ml) were added to the residue and the mixture was stirred at 60 C for 1.5 hours. The methanol was mostly distilled off under reduced pressure and the aqueous layer was made alkaline with ammonia, followed by addition of sodium acid sulfite (5.7 g). The mixture was extracted with chloroform and the chloroform layer was concentrated to dryness to give the above-identified compound (crude, 3.95 g). This product can be submitted to the next reaction step directly without further purification. NMR(CDC13, 60MHz): 6 0.83(t, 3H), 1.20(bs, 10H), 2.70(t, 2H), 4.07(bs, 4H), 4.40(bs, 2H), 7.20(m, llH) Reference Example 5 Production of 5-N,N-diisobutylaminomethyl-2-octanoyl aminopyrrolo [2, 3-dj pyrimidine-4-thione 2-Octanoylaminopyrrolot2,3-d]pyrimidine-4-thione (3.5 g) was reacted with diisobutylamine (4.5 g) in the same manner as Reference Example 4 to give the aboveidentified compound (crude, 2.3 g). NMR(CDC13, 60MHz): 6 0.85(t, 3H), 0.90(d, 12H), 1.20 2.00(m, 12H), 2.40-2.70(m, 6H), 4.40(bs, 2H), 7.20(bs, 1H) Example 1 Production of 2-amino-5-[ (3S,4R,5S)-4,5-dihydroxycyclo pent-l-en-3-ylaminomethylpyrrolo[2,3-dJpyrimidine-4- thione (6-thio Q base) The crude 5-N,N-dibenzylaminomethyl-2-octanoylamino pyrrolof2,3-d]pyrimidine-4-thione (3.3 g) as obtained in Reference Example 4 and (3S,4R,5S)-4,5-O-isopropylidene4,5-dihydroxycyclopent-l-en-3-ylamine (1.55 g) were dissolved in ethanol (150 ml) and the reaction was allowed to proceed in a sealed tube at 750C for 20 hours. After cooling, tetrahydrofuran (75 ml) and then a 40% aqueous solution of potassium hydroxide t11 ml) were added to the reaction mixture and the resulting mixture was allowed to stand at 50C for 3 days followed by addition of a 30% aqueous solution of ammonium chloride (11 ml). The mixture was concentrated to dryness and the residue was separated and purified by silica gel column chromatography using ethanol/chloroform (1:4) containing 7% NH3 as the eluent to give 2-amino-5-I(3S,4R,5S)-4,5-O-isopropylidene-4,5- dihydroxyCyclopent-l-en-3-ylaminomethyllpyrrolo[2,3-dl- pyrimidine-4-thione. The whole amount of this product was dissolved in methanol (100 ml) and 2N-HC1 (16 ml) and the solution was allowed to stand at room temperature overnight and then concentrated to dryness to give the above-identified compound in the dihydrochloride form t1.07 gl. NMR(D2O, 60MHz): 6 4.20-4.60(m, 2H), 4.47(bs, 2H), 6.13(m, 2H), 7.03(s, lH), lR(KBr): v 2930, 2780, 1690, 1590, 1200 cm Example 2 Production of 2-amino-5-aminomethylpyrrolot2,3-d]pyrimidine- 4-thione (6-thio Pre Q1 base) The crude 5-N,N-dibenzylaminomethyl-2-octanoylamino pyrrolot2,3-djpyrimidine-4-thione (1.0 g) as obtained in Reference Example 4 was dissolved in a mixture of ethanol t50 ml), tetrahydrofuran (30 ml) and concentrated aqueous ammonia (20 ml) and the reaction was allowed to proceed in a sealed tube at 800C for 1.5 hours. The solvent was then distilled off under reduced pressure and the residue was washed with ether. The insoluble matter was separated and purified with the aid of cellulose powder (Avicel, Asahi Chemical Industry Co., Ltd.,Japan) using concentrated ammonia-saturated n-butanol as the eluent to give the above-identified compound t215 mg). The physico-chemical determinations were made on the hydrochloride obtained by conversion with methanolic hydrochloric acid. NMRCD2O/CD3OD, 60MHz): 6 4.13(bs, 2H), 6.90(bs, lH) IR(KBr): v 2920, 1690, 1595, 1195 cm Example 3 Production of 2-amino-5-isoamylaminomethylpyrrolo[2,3-d]- pyrimidine-4-thione The crude 5-N,N-dibenzylaminomethyl-2-n-octanoyl aminopyrroloi2,3-dgpyrimidine-4-thione (2.01 g; 4 milimole) as obtained in Reference Example 4 and isoamylamine (1.75 g; 20 milimole) were dissolved in methanol (200 ml), and the reaction was allowed to proceed at 550C for 17 hours under stirring. The reaction mixture was concentrated under reduced pressure, the crystals emerged were recovered and washed with a small amount of methanol and ether and then dried, whereby the product (0.89 g) was obtained. NMRCDMSO-d6, 90MHz): 6 0.83(d, 6H), 1.03-1.60(m, 3H), 2.28(t, 2H), 3.70(s, 2H), 6.63(s, 1H) IR(KBr): v 3350, 3200, 3100, 2960, 1600, 1540, 1460, 1320, 1240, 1200, 1025, 945 cm Example 4 In a similar manner to that of Example 3, the crude 5-N,N-dibenzylaminomethyl-2-n-octanoylaminopyrrolo[2,3-d]- pyrimidine-4-thione (4 milimole) is reacted with an amine [Compound (III), 20 milimole] , whereby the following 7-deazapurine derivatives compound (I)] were obtained. It should be noted that, in the physico-chemical properties, the data of NMR are those measured at 90MHz employing DMSO-d6 as a solvent, and the data of IR are those measured by employing KBr as a solvent. (.1) Product: 2-Amino-5-(2-hydroxybenzylaminomethyl) - pyrrolo[2,3-d]pyrimidine-4-thione Yield: 1.07 (g) Properties: NMR: 6 3.80(s, 2H), 3.83(s, 2H), 6.70 (s, 1H), 6.60-6.75(m, 2H), 6.95-7.17(m, 2H), IR: v 3200, 1620, 1595, 1565, 1460, 1380, 1250, 1020 cm-1 Compound (III): EMI20.1 (2) Product: 2-Amino-5-cyclopentylaminomethylpyrrolo [2, 3-djpyrimidine-4-thione Yield: 0.99 (g) Properties: NMR: 6 1.20-1.83(m, 8H), 2.84-3.13(m, lH), 3.73(s, 2H), 6.67(s, 1H) IR: v 3180, 1640, 1590, 1560, 1535, 1490, 1360 cme-1 Compound (III): EMI20.2 (3) Product: 2-Amino-5-[2-(2-hydroxyethoxy)ethylamino methyl]pyrrolo[2,3-d]pyrimidine-4-thione Yield: 0.47 g Properties: NMR: 6 2.57(t, 2H), 3.30-3.56(m, 6H), 3.77(s, 2H), 6.67(s, lH) IR: v 3200, 2950, 1640, 1590, 1540, 1480, -l 1390 cm Compound (III): EMI20.3 (4) Product: 2-Amino-5-piperidinomethylpyrrolo [2,3-d] - pyrimidine-4-thione Yield: 0.58 (g) Properties: NMR: 6 1.43(s, 6H), 2.33-2.50(s, 4H), 3.87(s, 2H), 6.63(s, lH) IR: v 3150, 2950, 1620, 1590, 1535, 1460, 1240, 1020 cm Compound (III): EMI21.1 (5) product: 2-Amino-5-allylaminomethylpyrrolo [2, 3-d] - pyrimidine-4-thione Yield: 0.57 (g) Properties: NMR: 6 3.10(d,+2H), 3.76(s, 2H), 4.93-5.27 (m, 2H), 5.63-6.07(m, 1H), 6.68(s, 1H) IR: v 3200, 1630, 1590, 1540, 1465, 1240, 1020 cm Compound (III): CH2=CHCH2NH2 (6) Product: 2-Amino-5-I2-(2-aminoethylamino)ethylamino- methyl]pyrrolo[2,3-d]pyrimidine-4-thione Yield: 0.40 (g) Properties: NMR:# 2.57(s, 8H), 3.80(s, 2H), 6.70(s, lH) IR: v3300, 2920, 1590, 1535, 1465, 1235, 1020 cm 1 Compound (III): EMI21.2 (7) Product: 2-Amino-5-phenylaminomethylpyrrolo [2, 3-d]- pyrimidine-4-thione Yield: 0.67 (g) Properties: NMR: 6 4.40(s, 2H), 6.73(s, 1H), 6.47-6.63 (m, 3H), 6.93-7.10(m, 2H) IR: v 3320, 1625, 1600, 1565, 1440, 1385, 1200 cm 1 Compound (III): EMI21.3 (8) Product: 2-Amino-5-(2-hydroxyphenylaminomethyl) - pyrroloC2,3-d3pyrimidine-4-thione Yield: 0.31 (gS Properties: NMR: 6 4.42(s, 2H), 6.27-6.70(m, 4H), 6.75(d, 1H) IR: v 3340, 1625, 1595, 1565, 1440, 1200, -I 965 cm Compound (III): EMI22.1 (9) Product: 2-Amino-5-tert-butoxycarbonylmethylamino methylpyrrolo[2,3-d]pyrimidine-4-thione Yield: 0.54 (g) Properties: NMR: 6 1.37(s, 9H), 3.13(s, 2H), 3.82(s, 2H), 6.68(s, lH) IR: v 3350, 3150, 1730, 1650, 1560, 1365, 1235 cm 1 Compound tIII): EMI22.2

Claims: What we claimed is: 1. A 7-deazapurine derivative of the formula: EMI23.1 wherein R1 is hydrogen atom or an acyl group and R4 and R5 each is a hydrogen atom or a hydrocarbon residue which may optionally have one or more substituents or R4 and R5, together with the adjacent nitrogen atom, form a cyclic amino group. 2. A compound as claimed in Claim 1, wherein R1 is hydrogen. 3. A compound as claimed in Claim 1, wherein the acyl group is one having the molecular weight of not more than about 400. 4. A compound as claimed in Claim 1, wherein R4 and R5 are hydrogen atoms. 5, A compound as claimed in Claim 1, wherein R4 is hydrogen and R5 is a hydrocarbon residue having the molecular weight of not more than about 400. 6. A compound as claimed in Claim 5, wherein the hydrocarbon residue is an alkyl group of 1 to 18 carbon atoms which may be substituted. 7. A compound as claimed in Claim 5, wherein the hydrocarbon residue is an aryl group of 6 to 10 carbon atoms which may be substituted. 8. A compound -as claimed in Claim 5, wherein the hvdro- carbon residue is a cycloalkyl group of 3 to 12 carbon atoms which may be substituted. 9. A compound as claimed in Claim 1, wherein R4 and R5, together with the adjacent nitrogen atom, form a cyclic amino group of 4- to 10-membered ring which may be substituted. 10. A method of producing 7-deazapurine derivatives of the formula: EMI24.1 wherein R1 is a hydrogen atom or an acyl group and R4 and R5 each is a hydrogen atom or a hydrocarbon residue which may optionally have one or more substituents or Rq and R5, together with the adjacent nitrogen atom, form a cyclic amino group, which comprises subjecting a 7-deazapurine derivative of the formula: EMI24.2 wherein R1 is as defined above and R2 and R3 each is an alkyl, alkenyl or aralkyl group containing a methylene group in the position thereof or R2 and R3, together with the adjacent nitrogen atom, form a cyclic amino group, to substitution reaction with an amine of the formula: EMI25.1 wherein R4 and R5 have the same meaning as defined above.

Inventors: AKIMOTO, HIROSHI, NISHIMURA, SUSUMU, NOMURA, HIROAKI
Applicants: TAKEDA CHEMICAL INDUSTRIES, LTD.
Application year: 1984
Main classification: C07D487
IPC codes: C07D487